Literature DB >> 7439251

Effects and plasma levels of propranolol and metoprolol in hyperthyroid patients.

O R Nilsson, A Melander, L Tegler.   

Abstract

The effects and plasma concentrations of different doses of propranolol and metoprolol were studied in 34 hyperthyroid patients. The initial daily doses were propranolol 160 mg or metoprolol 200 mg. If the resting heart rate remained above 75 beats per min after treatment for 4-7 days, the dose was increased and the patient re-examined after a further 4-7 days. Propranolol (n = 17) caused a reduced heart rate, a decrease in serum 3,3',5-triiodothyronine (T3) and an increase in serum 3,3',5'-triiodothyronine (reverse T3, rT3). In 10 patients, there was no change in T3 or rT3 until the daily dose of propranolol had been increased to 240 or 320 mg. The plasma level of propranolol was significantly correlated with the decrease in T3 and the increase in rT3. Metoprolol (n = 17) caused a reduction in heart rate similar to that following propranolol. However, serum T3 was only slightly reduced even after an increase in dose to 300 or 400 mg, and serum rT3 was not altered. Metoprolol concentrations were not significantly correlated with the fall in T3. It appears that the influence of beta-blockers on T4 conversion is of little importance for the clinical improvement in hyperthyroid patients, and rather it is a consequence of beta 1-adrenergic blockade interfering with the effect of T3. In addition, the findings support the assumption that therapeutic failure with beta-blockers in hyperthyroidism may be due to suboptimal treatment, and that individualized dosage is necessary.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7439251     DOI: 10.1007/bf00561388

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

1.  Statistical methods applied to the clinical diagnosis of thyrotoxicosis.

Authors:  J CROOKS; I P MURRAY; E J WAYNE
Journal:  Q J Med       Date:  1959-04

2.  Quantitative determination of metoprolol in plasma and urine by gas chromatography.

Authors:  M Ervik
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

3.  Variable plasma propranolol levels in thyrotoxicosis.

Authors:  S Rubenfeld; V E Silverman; K M Welch; L E Mallette; P O Kohler
Journal:  N Engl J Med       Date:  1979-02-15       Impact factor: 91.245

4.  The influence of beta-adrenoceptor blocking agents on plasma thyroxine and triiodothyronine.

Authors:  W M Wiersinga; J L Touber
Journal:  J Clin Endocrinol Metab       Date:  1977-08       Impact factor: 5.958

5.  Effects of beta blockade on the peripheral manifestations of thyrotoxicosis.

Authors:  W Grossman; N I Robin; L W Johnson; H Brooks; H A Selenkow; L Dexter
Journal:  Ann Intern Med       Date:  1971-06       Impact factor: 25.391

6.  Non-selective and selective beta-1-adrenoceptor blocking agents in the treatment of hyperthyroidism.

Authors:  O R Nilsson; B E Karlberg; B Kågedal; L Tegler; S Almqvist
Journal:  Acta Med Scand       Date:  1979

7.  A radioimmunoassay for 3,3',5'-L-triiodothyronine (reverse T3): assessment of thyroid gland content and serum measurements in conditions of normal and altered thyroidal economy and following administration of thyrotropin releasing hormone (TRH) and thyrotropin (TSH).

Authors:  K D Burman; R C Dimond; F D Wright; J M Earll; J Bruton; L Wartofsky
Journal:  J Clin Endocrinol Metab       Date:  1977-04       Impact factor: 5.958

8.  Comparison of propranolol and practolol in the management of hyperthyroidism.

Authors:  L E Murchison; P D Bewsher; M I Chesters; W R Ferrier
Journal:  Br J Clin Pharmacol       Date:  1976-04       Impact factor: 4.335

9.  Determination of propranolol and six metabolites in human urine by high-pressure liquid chromatography.

Authors:  J F Pritchard; D W Schneck; A H Hayes
Journal:  J Chromatogr       Date:  1979-01-01

10.  Comparison of propranolol and metoprolol in the management of hyperthyroidism.

Authors:  L E Murchison; J How; P D Bewsher
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

View more
  8 in total

Review 1.  Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.

Authors:  J Feely
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

2.  Relationship between dose, blood level and haemodynamic response in patients with cirrhosis receiving propranolol.

Authors:  M I Jirón; B Delhotal; D Lebrec
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Influence of hyperthyroidism on the kinetics of methimazole, propranolol, metoprolol and atenolol.

Authors:  B Hallengren; O R Nilsson; B E Karlberg; A Melander; L Tegler; E Wåhlin-Boll
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  The use of a selective beta-adrenergic receptor blocker for the preoperative preparation of thyrotoxic patients.

Authors:  P Dial; P R Hastings
Journal:  Ann Surg       Date:  1982-12       Impact factor: 12.969

5.  Influence of beta-adrenoceptor blocking agents on lymphocyte function in vitro.

Authors:  B Hallengren; A Forsgren; A Melander
Journal:  Br J Clin Pharmacol       Date:  1982-04       Impact factor: 4.335

6.  Nadolol in thyrotoxicosis.

Authors:  N R Peden; T E Isles; I H Stevenson; J Crooks
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 7.  Use of beta-adrenoceptor blocking drugs in hyperthyroidism.

Authors:  J Feely; N Peden
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

8.  Hypothalamic-pituitary-thyroid axis function in women with a menstrually related mood disorder: association with histories of sexual abuse.

Authors:  Adomas Bunevicius; Jane Leserman; Susan S Girdler
Journal:  Psychosom Med       Date:  2012-09-21       Impact factor: 4.312

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.